Acromegaly is a rare and debilitating disease resulting from the overproduction of growth hormone (GH), most often due to a pituitary tumor. Overproduction of GH results in persistent elevation in levels of insulin-like growth factor I (IGF-I).

SOMAVERT is the first and only growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.

SOMAVERT selectively binds to GH receptors on all cell surfaces, where it blocks the binding of the bodys own GH. Reducing the amount of binding of the bodys GH results in decreased serum IGF-I levels.

SOMAVERT can be ordered by your physician through the Bridge ProgramTM, a specialty pharmacy and reimbursement assistance program that serves patients who are prescribed SOMAVERT.

If you have been diagnosed with acromegaly or suspect that you may have acromegaly, talk to your physician and ask if SOMAVERT is right for you.

Please also refer to the WARNINGS and PRECAUTIONS sections.

Patients and any other persons who may administer SOMAVERT should be carefully instructed by a health care professional on how to properly reconstitute and inject the product (see enclosed instructions).

Patients should be informed about the need for serial monitoring of LTs, and told to immediately discontinue therapy and contact their physician if they become jaundiced. In addition, patients should be made aware that serial IGF-I levels will need to be obtained to allow their physician to properly adjust the dose of SOMAVERT .

Bookmark this page: